medmix Half-Year 2023 Results
Ad hoc announcement pursuant to Art. 53 LR
Solid underlying business momentum in H1 2023 restrained by transitory factors
Strong performance expected in H2 2023 with mid-term outlook confirmed
New FY 2023 profit margin guidance reflects timing factors within H2 2023